CNBX Pharmaceuticals Inc.Financials
|
|
Historical Financials
DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 | DEC 2019 | DEC 2018 | DEC 2017 | DEC 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | - | 130,074 | 410,165 | 29,958 | - | 7,157 | 9,843 | 9,601 | 5,684 | 112,500 | |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | |
| Gross Profit | - | - | - | - | - | - | - | - | 5,684 | 112,500 |
Sign up to view full financial statements
Create a free CapEdge account to access balance sheet, cash flow, and complete historical data.
DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 | DEC 2019 | DEC 2018 | DEC 2017 | DEC 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin (%) | |||||||||||
| R&D Expense | |||||||||||
| SG&A Expense | |||||||||||
| Total Operating Expenses | |||||||||||
| Operating Income or Loss | |||||||||||
| Operating Margin (%) | |||||||||||
| EBITDA | |||||||||||
| Interest Expense | |||||||||||
| Non-Operating Income/Expense | |||||||||||
| Net Income | |||||||||||
| Net Profit Margin (%) | |||||||||||
| Basic EPS | |||||||||||
| Diluted EPS | |||||||||||
| Basic Average Shares | |||||||||||
| Diluted Average Shares |
All numbers in thousands. Financial statements are in beta and sourced from EDGAR XBRL filings. Read the caveats.